Mark D Pegram
Overview
Explore the profile of Mark D Pegram including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
4571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanft T, Wong J, ONeal B, Siuliukina N, Jankowitz R, Pegram M, et al.
J Natl Compr Canc Netw
. 2024 Mar;
22(2):99-107.
PMID: 38437792
Background: The Breast Cancer Index (BCI) test assay provides an individualized risk of late distant recurrence (5-10 years) and predicts the likelihood of benefitting from extended endocrine therapy (EET) in...
2.
Muller V, Bartsch R, Lin N, Montemurro F, Pegram M, Tolaney S
Cancer Treat Rev
. 2023 Mar;
115:102527.
PMID: 36893691
Background: There is an increasing need for developing effective therapies for managing intracranial disease in patients with human epidermal growth factor receptor 2-positive (HER2 +) metastatic breast cancer and brain...
3.
Rugo H, Im S, Cardoso F, Cortes J, Curigliano G, Musolino A, et al.
J Clin Oncol
. 2022 Nov;
41(2):198-205.
PMID: 36332179
JCO Final overall survival (OS) in SOPHIA (ClinicalTrials.gov identifier: NCT02492711), a study of margetuximab versus trastuzumab, both with chemotherapy, in patients with previously treated human epidermal growth factor receptor 2-positive...
4.
Ma C, Luo J, Freedman R, Pluard T, Nangia J, Lu J, et al.
Clin Cancer Res
. 2022 Jan;
28(7):1258-1267.
PMID: 35046057
Purpose: HER2 mutations (HER2mut) induce endocrine resistance in estrogen receptor-positive (ER+) breast cancer. Patients And Methods: In this single-arm multi-cohort phase II trial, we evaluated the efficacy of neratinib plus...
5.
Musolino A, Gradishar W, Rugo H, Nordstrom J, Rock E, Arnaldez F, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 34992090
Several therapeutic monoclonal antibodies (mAbs), including those targeting epidermal growth factor receptor, human epidermal growth factor receptor 2 (HER2), and CD20, mediate fragment crystallizable gamma receptor (FcγR)-dependent activities as part...
6.
Kim J, Liang W, Kang C, Pegram M, Herr A
PLoS One
. 2021 Jul;
16(7):e0254783.
PMID: 34314438
An array of isoforms of the nuclear estrogen receptor alpha (ER-α) protein contribute to heterogeneous response in breast cancer (BCa); yet, a single-cell analysis tool that distinguishes the full-length ER-α66...
7.
Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, et al.
Proc Natl Acad Sci U S A
. 2021 Jul;
118(29).
PMID: 34257155
Trastuzumab, a targeted anti-human epidermal-growth-factor receptor-2 (HER2) monoclonal antibody, represents a mainstay in the treatment of HER2-positive (HER2) breast cancer. Although trastuzumab treatment is highly efficacious for early-stage HER2 breast...
8.
Pegram M, Hamilton E, Tan A, Storniolo A, Balic K, Rosenbaum A, et al.
Mol Cancer Ther
. 2021 May;
20(8):1442-1453.
PMID: 34045233
MEDI4276 is a biparatopic tetravalent antibody targeting two nonoverlapping epitopes in subdomains 2 and 4 of the HER2 ecto-domain, with site-specific conjugation to a tubulysin-based microtubule inhibitor payload. MEDI4276 demonstrates...
9.
Rugo H, Im S, Cardoso F, Cortes J, Curigliano G, Musolino A, et al.
JAMA Oncol
. 2021 Jan;
7(4):573-584.
PMID: 33480963
Importance: ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but...
10.
Fernandes L, Epstein C, Bobe A, Bell J, Stumpe M, Salazar M, et al.
Clin Breast Cancer
. 2021 Jan;
21(4):e340-e361.
PMID: 33446413
Objective/background: We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence....